Pancreatic Cyst Molecular Analysis for Diagnostic Accuracy
Solution Overview
Problem
Current methods for diagnosing pancreatic cancer and pre-cancerous states are hindered by the indeterminate nature of pancreatic cysts, with existing imaging and cytological analysis techniques failing to reliably distinguish between malignant and pre-malignant cysts, leading to suboptimal diagnostic accuracy and inability to predict the presence of invasive cancer.
Innovation Solution
A method involving molecular analysis of pancreatic cyst fluid, including optical density analysis, quantitative PCR, competitive template PCR, and mutation analysis to determine DNA quality and quantity, presence of tumor suppressor gene mutations, and temporal sequence of mutation accumulation, which helps differentiate between cancerous and non-cancerous states.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If imaging and cyst aspirate analysis are used to evaluate pancreatic cysts, then the diagnostic process is non-invasive and relatively simple, but the ability to reliably distinguish malignant from pre-malignant cysts is insufficient
Solution Approach 1:
The invention changes the parameters being measured from simple imaging characteristics and basic cytology to comprehensive molecular parameters including DNA quality, DNA quantity, and specific gene mutations (K-ras, p16, p53, DPC4). This parameter transformation enables reliable distinction between malignant and pre-malignant cysts by detecting molecular alterations that precede morphological changes.
Solution Approach 2:
The invention replaces mechanical/pathological examination methods with molecular analysis techniques. Instead of relying on microscopic examination of cells and tissue architecture, the method uses PCR-based molecular detection to identify genetic alterations, substituting mechanical pathology with biochemical analysis for more accurate diagnosis.
2Measurement precision
If traditional pathology examination methods are used, then the diagnostic approach is well-established and relatively simple, but the indeterminate diagnosis rate is over 50% and early pancreatic cancer cannot be reliably detected
Solution Approach 1:
The invention performs preliminary molecular analysis on cyst fluid before surgical intervention or when no solid mass is present. By detecting molecular alterations (DNA mutations, quality changes) in the cyst fluid itself, the method provides early diagnosis before traditional pathology can detect morphological changes, enabling intervention at a more treatable stage.
Solution Approach 2:
The invention uses cyst fluid as an intermediary medium to access molecular information from the cyst lining. Rather than directly examining the cyst wall or requiring surgical resection, the fluid serves as a surrogate that contains DNA and molecular markers reflecting the genetic status of the cyst epithelium, enabling indirect but accurate diagnosis.
3Reliability
If endoscopic ultrasound is used to secure representative specimens, then tissue sampling is achieved, but reliable differentiation of malignant from pre-malignant cysts remains impossible without advanced molecular analysis
Solution Approach 1:
The invention creates a universal diagnostic protocol that can evaluate all pancreatic cysts regardless of their current stage (pre-malignant or malignant) or presence of solid components. The molecular analysis panel (DNA quality, quantity, K-ras, p16, p53, DPC4) provides a single comprehensive test that works for all cyst types, replacing the need for different diagnostic approaches based on cyst characteristics.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach significantly improves the diagnostic accuracy for pancreatic cancer and pre-cancerous states by providing a definitive method to distinguish between malignant and non-malignant conditions, enabling early detection and appropriate treatment planning.
Implementation Method 1
performing an optical density analysis of the aspirate to determine DNA quantity
Implementation Method 2
performing a quantitative PCR analysis of the aspirate to determine DNA quality
Implementation Method 3
performing competitive template PCR to determine DNA quality
Implementation Method 4
performing mutation analysis of the DNA in the aspirate comprising determining the presence of mutations in a tumor suppressor gene
Data Source
AI summary
The application relates to a method of a predicting the presence of invasive pancreatic cancer or high grade dysplasia, pre-cancerous pancreatic states and non-neoplastic conditions comprising detailed molecular analysis incorporating DNA quality and quantity, K-ras mutational analysis and a broad spectrum of tumor suppressor gene linked microsatellite LOH. Methods of diagnosing, determining prognosis of and determining a course of treatment for pancreatic cancer or high grade dysplasia, pre-cancerous pancreatic states and non-neoplastic conditions are also provided.